| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NG0994-22 |
| P698 | PubMed publication ID | 7987388 |
| P50 | author | Rosalind Eeles | Q24640445 |
| Nelleke A Gruis | Q42392971 | ||
| P2093 | author name string | Kamb A | |
| Liu Q | |||
| Tran T | |||
| Ding W | |||
| Miki Y | |||
| Hussey C | |||
| Shattuck-Eidens D | |||
| Weaver-Feldhaus J | |||
| P2860 | cites work | A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 | Q24322196 |
| Mutation and cancer: statistical study of retinoblastoma | Q24618185 | ||
| Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers | Q28251857 | ||
| A cell cycle regulator potentially involved in genesis of many tumor types | Q28251933 | ||
| Mammalian G1 cyclins | Q29618855 | ||
| Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. | Q34046828 | ||
| Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas | Q35648205 | ||
| Homozygous deletions within human chromosome band 9p21 in melanoma | Q37286548 | ||
| p53: at the crossroads of molecular carcinogenesis and risk assessment | Q40793098 | ||
| Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22 | Q44552643 | ||
| Clinical and genetic studies in six Dutch kindreds with the dysplastic naevus syndrome | Q47410441 | ||
| Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees. | Q54261736 | ||
| Hereditary melanoma in Australia variable association with dysplastic nevi and | Q58025042 | ||
| P16 gene in uncultured tumours | Q59058147 | ||
| Exclusion of the dysplastic nevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage studies in Dutch families | Q69225441 | ||
| Rates of p16 (MTS1) mutations in primary tumors with 9p loss | Q72041274 | ||
| All in the (cancer) family | Q72635284 | ||
| Response | Q94596609 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | susceptibility locus | Q62091149 |
| P304 | page(s) | 23-26 | |
| P577 | publication date | 1994-09-01 | |
| P1433 | published in | Nature Genetics | Q976454 |
| P1476 | title | Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus | |
| P478 | volume | 8 |
| Q55480673 | 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers |
| Q36687252 | A CDKN2-like polymorphism in Xiphophorus LG V is associated with UV-B-induced melanoma formation in platyfish-swordtail hybrids |
| Q55670980 | A Familial Syndrome of Pancreatic Cancer and Melanoma with a Mutation in theCDKN2Tumor-Suppressor Gene |
| Q88371437 | A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma |
| Q36808635 | A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). |
| Q48498516 | A comprehensive survey of cancer risks in extended families. |
| Q48825624 | A genome-wide association study identifies novel single nucleotide polymorphisms associated with dermal shank pigmentation in chickens |
| Q38442858 | A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation |
| Q34390025 | A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs |
| Q34283555 | A novel p16(INK4A) mutation associated with esophageal squamous cell carcinoma in a high risk population |
| Q40227530 | A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family |
| Q37104946 | A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer |
| Q45769777 | A research shortcut from a common cold virus to human cancer |
| Q34142079 | A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families |
| Q53237784 | A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q. |
| Q77658607 | Aberrations in the MTS1 tumor suppressor locus in oral squamous cell carcinoma lines preferentially affect the INK4A gene and result in increased cdk6 activity |
| Q36843805 | Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature? |
| Q58485779 | Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma |
| Q74268765 | Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus |
| Q73504522 | Allelic loss at the D9S171 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma |
| Q78757756 | Allelic loss on chromosomes 2q, 3p and 21q: possibly a poor prognostic factor in oral squamous cell carcinoma |
| Q56418625 | Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia |
| Q48877020 | Alterations of cell cycle regulators in gliomatosis cerebri |
| Q38861630 | Altered microRNA Expression Profiles and Regulation of INK4A/CDKN2A Tumor Suppressor Genes in Canine Breast Cancer Models |
| Q28253911 | An automated procedure to identify biomedical articles that contain cancer-associated gene variants |
| Q38705693 | An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies. |
| Q37204679 | Applications of genomics in melanoma oncogene discovery |
| Q33680576 | Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma |
| Q34212766 | Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study |
| Q35090029 | BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model |
| Q89499162 | Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation |
| Q50610892 | Bilateral primary uveal melanoma. Bad luck or bad genes? |
| Q28281959 | Biochemical characterization of p16INK4- and p18-containing complexes in human cell lines |
| Q28294919 | Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase |
| Q57571832 | CDK4 inhibitors an emerging strategy for the treatment of melanoma |
| Q30353881 | CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients. |
| Q39012719 | CDKN2A unclassified variants in familial malignant melanoma: combining functional and computational approaches for their assessment. |
| Q57282544 | CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters |
| Q34322773 | Cancer-associated genodermatoses and familial cancer syndromes with cutaneous manifestations |
| Q42064477 | Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity |
| Q43123105 | Canine Mammary Carcinomas: A Comparative Analysis of Altered Gene Expression |
| Q41099892 | Cdk inhibitors in development and cancer |
| Q34076478 | Cell cycle checkpoints and their inactivation in human cancer |
| Q38466264 | Cell cycle proteins and the development of oral squamous cell carcinoma. |
| Q33895611 | Cell-cycle inhibitors: three families united by a common cause |
| Q40514881 | Cell-cycle regulators and cancer |
| Q28280872 | Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis |
| Q35746432 | Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups |
| Q38503862 | Chromosomal and genetic alterations of 7,12-dimethylbenz[a]anthracene-induced melanoma from TP-ras transgenic mice |
| Q35644518 | Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. |
| Q41285090 | Clinical implications of cytogenetic abnormalities in melanoma |
| Q28544919 | Clonal architectures and driver mutations in metastatic melanomas |
| Q36880772 | Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations |
| Q37355423 | Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours |
| Q57461758 | Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine |
| Q24563733 | Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21 |
| Q55388589 | Contribution of Chromosome 9p21‐22 Deletion to the Progression of Human Renal Cell Carcinoma |
| Q34553243 | Creation of a national resource with linked genealogy and phenotypic data: the Veterans Genealogy Project |
| Q26782090 | Cross-species models of human melanoma |
| Q26781652 | Current State of Animal (Mouse) Modeling in Melanoma Research |
| Q37890286 | Current status of genome-wide association studies in cancer |
| Q59377158 | Cutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT |
| Q34155632 | Cyclin-dependent kinase 1 expression is inhibited by p16(INK4a) at the post-transcriptional level through the microRNA pathway |
| Q77747524 | Cytogenetic characterization of 22 human renal cell tumors in relation to a histopathological classification |
| Q40803117 | DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients |
| Q36621655 | Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group. |
| Q88660687 | Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma |
| Q42415481 | Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma |
| Q87822617 | Deletion of the MGMT gene in familial melanoma |
| Q36317675 | Deoxyribonucleic acid (DNA) methyltransferase contributes to p16 promoter CpG island methylation in lung adenocarcinoma with smoking |
| Q34093068 | Differentiation therapy of human cancer: basic science and clinical applications |
| Q30203298 | Discussion of photoprotection, screening, and risk behaviors with children and grandchildren after melanoma genetic testing |
| Q34537149 | Disruption of oncogene/tumor suppressor networks during human carcinogenesis |
| Q55397223 | Dissecting the Mutational Landscape of Cutaneous Melanoma: An Omic Analysis Based on Patients from Greece. |
| Q37667766 | Doxycycline-Regulated p16MTS1 Expression Suppresses the Anchorage-Independence and Tumorigenicity of Breast Cancer Cell Lines that Lack Endogenous p16. |
| Q48092515 | Emerging Biomarkers in Cutaneous Melanoma. |
| Q35105665 | Epidemiology of malignant melanoma |
| Q33914379 | Evidence for a heritable predisposition to Chronic Fatigue Syndrome |
| Q36796431 | Evidence for an Environmental and Inherited Predisposition Contributing to the Risk for Global Tendinopathies or Compression Neuropathies in Patients With Rotator Cuff Tears |
| Q41947566 | Evidence for an inherited predisposition contributing to the risk for rotator cuff disease |
| Q40876018 | Expression and role of p27(kip1) in neuronal differentiation of embryonal carcinoma cells |
| Q38475192 | Expression of p 16 protein in prostatic adenocarcinomas, intraepithelial neoplasia, and benign/hyperplastic glands |
| Q35746653 | Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas |
| Q61804952 | Familial Melanoma: Diagnostic and Management Implications |
| Q38671435 | Familial Pancreatic Cancer and the Future of Directed Screening |
| Q80638828 | Familial aggregation of age-related macular degeneration in the Utah population |
| Q40900637 | Familial atypical multiple mole melanoma (FAMMM) syndrome: history, genetics, and heterogeneity |
| Q33880310 | Familial clustering of endometrial cancer in a well-defined population |
| Q28391589 | Familial malignant melanoma - overview |
| Q72874151 | Familial melanoma and p16--a hung jury |
| Q42370555 | Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history |
| Q37178980 | Familiality in brain tumors |
| Q71721193 | Frequency of homozygous deletion at p16/CDKN2 in primary human tumours |
| Q60895673 | Frequent allelic losses of 9p21 markers and low incidence of mutations at p16(CDKN2) gene in non-Hodgkin lymphomas of B-cell lineage |
| Q48154511 | Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines |
| Q35541602 | Frequent p16-independent inactivation of p14ARF in human melanoma |
| Q30322978 | Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information. |
| Q74788541 | Gain of 9p in the pathogenesis of polycythemia vera |
| Q37137000 | Genetic Determinants of Cutaneous Melanoma Predisposition |
| Q28285050 | Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer |
| Q31146223 | Genetic analysis of low BMI phenotype in the Utah Population Database |
| Q34568604 | Genetic and environmental factors in cutaneous malignant melanoma |
| Q37196687 | Genetic and environmental factors in head and neck cancer genesis |
| Q56893927 | Genetic and epidemiological risk factors for a malignant melanoma-predisposing phenotype: The great number of nevi |
| Q36612446 | Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. |
| Q48057808 | Genetic and functional evaluation of MITF as a candidate gene for cutaneous melanoma predisposition in pigs |
| Q36314787 | Genetic counseling in melanoma. |
| Q34783505 | Genetic insights into familial cancers-- update and recent discoveries |
| Q44633779 | Genetic markers of oral malignant melanoma analysed by fluorescence in situ hybridisation (FISH). |
| Q31889996 | Genetic mechanisms in squamous cell carcinoma of the head and neck |
| Q33681811 | Genetic predisposition to ocular melanoma |
| Q37544403 | Genetic risk factors for melanoma |
| Q37409032 | Genetics and genomics of melanoma |
| Q34449957 | Genetics of familial melanoma: 20 years after CDKN2A. |
| Q36563659 | Genetics of melanoma |
| Q36216850 | Genetics of primary intraocular tumors |
| Q40638691 | Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells |
| Q45194373 | Genital and anorectal mucosal melanoma is associated with cutaneous melanoma in patients and in families |
| Q93270780 | Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility |
| Q33814805 | Genome-wide association studies in cancer--current and future directions |
| Q34114293 | Genome-wide association study identifies five new breast cancer susceptibility loci |
| Q37341178 | Genome-wide association study identifies three loci associated with melanoma risk |
| Q41170258 | Genomic instability in 1p and human malignancies |
| Q56438333 | Germline Mutations of the CDKN2 Gene in UK Melanoma Families |
| Q28270834 | Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma |
| Q36694476 | Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma |
| Q38359923 | HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. |
| Q34622718 | Hereditary Pancreatic Cancer |
| Q73412079 | High frequency of homozygous deletion and methylation of p16(INK4A) gene in oral squamous cell carcinomas |
| Q36619726 | High prevalence of p16 genetic alterations in head and neck tumours |
| Q36499211 | High- and low-penetrance cutaneous melanoma susceptibility genes. |
| Q57948954 | Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds |
| Q39507954 | Homozygous deletions of p16(INK4) occur frequently in bilharziasis-associated bladder cancer |
| Q74266124 | How is the mutational status for tumor suppressors p53 and p16(INK4A) in MFH of the bone? |
| Q35435625 | Identification of PTEN mutations in metastatic melanoma specimens |
| Q36304955 | Identification, genetic testing, and management of hereditary melanoma. |
| Q36055045 | Impact of melanoma genetic test reporting on perceived control over melanoma prevention |
| Q40902031 | Inactivation of cyclin-dependent kinase inhibitor genes and development of human acute leukemias |
| Q40694393 | Inactivation of p16INK4a expression in malignant mesothelioma by methylation |
| Q73212035 | Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene |
| Q59548753 | Increased Melanocytic Nevi and Nevus Density in a G-34T CDKN2A/p16 Melanoma-Prone Pedigree |
| Q36641299 | Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes |
| Q55029059 | Infrequent somatic mutation of the MTS1 gene in primary bladder carcinomas. |
| Q28289708 | Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A |
| Q42182349 | Inhibitor of differentiation-4 (Id4) stimulates pigmentation in melanoma leading to histiocyte infiltration |
| Q40958606 | Inhibitors of cyclin-dependent kinase and cancer |
| Q54104985 | Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. |
| Q41236837 | Interphase cytogenetic analysis of solid tumors by non-isotopic DNA in situ hybridization |
| Q36502322 | Linkage analysis of extended high-risk pedigrees replicates a cutaneous malignant melanoma predisposition locus on chromosome 9q21. |
| Q42661850 | Linkage analysis of familial melanoma and chromosome 6 in 14 Australian kindreds |
| Q27852814 | Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines |
| Q73496858 | Loss of Heterozygosity at Chromosome 9p21 in Primary Neuroblastomas: Evidence for Two Deleted Regions |
| Q57287558 | Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors |
| Q52526330 | Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. |
| Q41130523 | Loss of heterozygosity on chromosome 9q21 (p16 gene) uncommon in soft-tissue sarcomas |
| Q34020538 | MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations |
| Q37211362 | Malignant melanoma in the 21st century: the emerging molecular landscape |
| Q36695641 | Management of familial melanoma |
| Q55078672 | Mapping of melanoma modifier loci in RET transgenic mice. |
| Q35098019 | Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway |
| Q34020543 | Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. |
| Q38730348 | Melanocytic nevi and melanoma: unraveling a complex relationship |
| Q38646092 | Melanoma Epidemiology and Prevention |
| Q37334503 | Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later |
| Q33726956 | Melanoma genetics and the development of rational therapeutics |
| Q50501346 | Melanoma in adolescents: a case-control study of risk factors in Queensland, Australia. |
| Q36712918 | Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants |
| Q56435948 | Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK |
| Q35137163 | Melanoma: Molecular Pathogenesis and Therapeutic Management |
| Q46071071 | Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors |
| Q77441892 | Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions |
| Q33739273 | Modeling human lung cancer in mice: similarities and shortcomings |
| Q35844857 | Modeling inheritance of malignant melanoma with DNA markers in Sinclair swine |
| Q57781575 | Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma |
| Q77619102 | Molecular biology of human melanoma development and progression |
| Q41528285 | Molecular diagnosis of pancreas carcinoma |
| Q41262814 | Molecular genetic approaches to non-melanoma and melanoma skin cancer |
| Q22010017 | Molecular identification of the human GABABR2: cell surface expression and coupling to adenylyl cyclase in the absence of GABABR1 |
| Q26795735 | Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets |
| Q57269052 | Mutation analysis of theCDKN2A promoter in Australian melanoma families |
| Q40978415 | Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma |
| Q24649783 | Mutation testing in melanoma families: INK4A, CDK4 and INK4D |
| Q41332196 | Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer |
| Q42631112 | Mutational analysis of CDKN2A gene in a group of 390 larynx cancer patients |
| Q70888925 | Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas |
| Q73258368 | Mutational analysis of the p16 gene in human neuroblastomas |
| Q52537796 | Mutations associated with familial melanoma impair p16INK4 function. |
| Q47691368 | Mutations in context: implications of BRCA testing in diverse populations |
| Q34107950 | New developments in melanoma genetics |
| Q55513422 | New susceptibility loci for cutaneous melanoma risk and progression revealed using a porcine model. |
| Q36643968 | No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours. |
| Q64108542 | Non-coding and Coding Transcriptional Profiles Are Significantly Altered in Pediatric Retinoblastoma Tumors |
| Q24652510 | Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6 |
| Q51000569 | Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin. |
| Q57228797 | Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase |
| Q61978803 | P16INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem |
| Q35739446 | POLE mutations in families predisposed to cutaneous melanoma |
| Q26865736 | Pathways and therapeutic targets in melanoma |
| Q33638941 | Perceived risk following melanoma genetic testing: a 2-year prospective study distinguishing subjective estimates from recall |
| Q35574952 | Pharmacogenetic candidate genes for melanoma |
| Q24806439 | Polymorphisms of the BRAF gene predispose males to malignant melanoma |
| Q35180844 | Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom |
| Q52857616 | Prevalence of 9p21 deletions in UK melanoma families. |
| Q34694716 | Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling |
| Q37409666 | Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population |
| Q41520554 | Prognostic Factors in Malignant Melanoma |
| Q33538422 | Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1. |
| Q35856673 | Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis |
| Q74020575 | Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors |
| Q41488826 | Recent insights into the functions of the retinoblastoma susceptibility gene product |
| Q34138129 | Recessive oncogenes: current status |
| Q92106577 | Regulation of Cell Cycle Entry and Exit: A Single Cell Perspective |
| Q41095685 | Retroviral introduction of the p16 gene into murine cell lines to elicit marked antiproliferative effects |
| Q58283406 | Risk of cutaneous melanoma associated with a family history of the disease |
| Q41710434 | Role of the cyclin-dependent kinase inhibitor CDKN2A in familial melanoma |
| Q45150040 | Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). |
| Q36615991 | Search for germline alterations in CDKN2A/ARF and CDK4 of 42 Jewish melanoma families with or without neural system tumours. |
| Q35840024 | Selection criteria for genetic assessment of patients with familial melanoma |
| Q73836193 | Selective deletion of p14(ARF) exon 1beta of the INK4a locus in oral squamous cell carcinomas of Indians |
| Q36007325 | Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death. |
| Q39737975 | Signatures of mutation and selection in the cancer genome |
| Q34218180 | Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiality by site |
| Q73631577 | Somatic INK4a-ARF locus mutations: a significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck |
| Q35019588 | Spectrum of molecular changes during hepatocarcinogenesis induced by DEN and other chemicals in Fischer 344 male rats. |
| Q44490652 | Spectrum of molecular changes during hepatocarcinogenesis induced by DEN and other chemicals in Fisher 344 male rats [Mechanisms of Ageing and Development 123 (2002) 1665-1680]. |
| Q56893701 | Sporadic multiple primary melanoma cases:CDKN2Agermline mutations with a founder effect |
| Q35015059 | Strong evidence for a genetic contribution to late-onset Alzheimer's disease mortality: a population-based study |
| Q24316348 | Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a |
| Q27639756 | Structure-based design of p18INK4c proteins with increased thermodynamic stability and cell cycle inhibitory activity |
| Q40955001 | Suppression of Ras-mediated NIH3T3 transformation by p19ARF does not involve alterations of cell growth properties |
| Q52539731 | Targeting the duality of cancer. |
| Q40019366 | Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma |
| Q36437816 | The CDKN2A (p16) gene and human cancer. |
| Q40483208 | The CDKN2A database: Integrating allelic variants with evolution, structure, function, and disease association |
| Q28145080 | The INK4 family of cell cycle inhibitors in cancer |
| Q33540080 | The INK4A/ARF locus and its two gene products |
| Q35146563 | The INK4a/ARF locus and melanoma |
| Q77362259 | The INK4a/ARF tumor suppressor: one gene--two products--two pathways |
| Q79435498 | The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry |
| Q45955388 | The MeLiM Minipig: An Original Spontaneous Model to Explore Cutaneous Melanoma Genetic Basis. |
| Q60909457 | The Power of Fish Models to Elucidate Skin Cancer Pathogenesis and Impact the Discovery of New Therapeutic Opportunities |
| Q34804764 | The RB and p53 pathways in cancer |
| Q74116641 | The Xiphophorus-derived antibody, XMEL, shows sensitivity and specificity for human cutaneous melanoma but is not a prognostic marker |
| Q38261369 | The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer |
| Q41226231 | The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds |
| Q36785968 | The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma |
| Q35938292 | The effects of transferring tumor suppressor gene p16INK4A to p16INK4A-deleted cancer cells |
| Q40525768 | The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity |
| Q33813969 | The genetics of hereditary melanoma and nevi. 1998 update |
| Q35190150 | The genetics of malignant melanoma: lessons from mouse and man. |
| Q73256080 | The genetics of melanoma |
| Q38718904 | The genomic landscape of cutaneous melanoma |
| Q64240247 | The interplay of CDK4 and CDK6 in melanoma |
| Q41175188 | The mammalian cell cycle in normal and abnormal growth |
| Q54317457 | The p16INK4a/CDKN2A tumor suppressor and its relatives. |
| Q54791332 | The presence of candidate tumor suppressor gene loci at chromosome 3p for oral squamous cell carcinomas. |
| Q38165149 | The role of polo-like kinase 1 in carcinogenesis: cause or consequence? |
| Q73582017 | The search for cancer risk factors: when can we stop looking? |
| Q40223298 | The synergic effect of HPV infection and epigenetic anomaly of the p16 gene in the development of cervical cancer |
| Q26782222 | Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer? |
| Q40935835 | Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus |
| Q24793291 | Transforming growth factor-beta and breast cancer: Cell cycle arrest by transforming growth factor-beta and its disruption in cancer |
| Q47557700 | Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma. |
| Q40494447 | Tumor Suppression: Lessons in p16 from phylum Falconium |
| Q38306855 | Tumour suppressors and cellular senescence |
| Q41335802 | Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition |
| Q42628813 | Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. |
| Q35787900 | UV wavelength-dependent DNA damage and human non-melanoma and melanoma skin cancer |
| Q34401911 | Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing |
| Q35739822 | Unfolding the mutational landscape of human melanoma |
| Q37710143 | Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway |
| Q38089070 | Use of SNPs in cancer predisposition analysis, diagnosis and prognosis: tools and prospects. |
| Q47228666 | Use of a genealogical database demonstrates heritability of pulmonary fibrosis |
| Q34716087 | Use of human tissue to assess the oncogenic activity of melanoma-associated mutations |
| Q36909926 | Utilizing of Adsorptive Transfer Stripping Technique Brdicka Reaction for Determination of Metallothioneins Level in Melanoma Cells, Blood Serum and Tissues. |
| Q40062598 | Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population |
| Q37287025 | Wnt-signaling and senescence: A tug of war in early neoplasia? |
| Q55476928 | cDNA expression array reveals heterogeneous gene expression profiles in three glioblastoma cell lines. |
| Q60077083 | p16 and melanoma |
| Q77402846 | p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma |
| Q41047190 | p16ink4a gene and hematological malignancies. |
| Q52540552 | p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. |
Search more.